Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe ...
A therapy that restores brain cells impaired by a rare genetic disorder may offer a strategy for treating conditions like ...
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window ATLANTA -- A novel antisense mRNA drug slashed triglycerides in higher risk or moderate hypertriglyceridemia patients ...
Both chemical and enzymatic synthesis companies need to continue working to overcome their respective hurdles.
The team led by Sergiu Pasca, from Stanford University, wants to test this promising strategy in children with Timothy ...
TipRanks ‘Perfect 10’ List: These 2 Top-Scoring Stocks Could Double (or More), According to Analysts
Every investor just wants to find the perfect stock – but finding the shares that check every box can be a challenge. The ...
Discover how Sarepta Therapeutics' patented antisense oligomers target collagen mRNA to treat dystrophic epidermolysis bullosa and related disorders.
To achieve this, we have used chemically modified antisense oligonucleotides to regulate Fas expression. Antisense oligonucleotides can reduce the expression of targeted messenger RNA through ...
By using antisense oligonucleotides to inhibit a mutated exon associated with Timothy syndrome mutation, researchers restored neuron function.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback